CoChat

Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer

Open access
Richman, Lee P., Vonderheide, Robert H. · 2014 · Cancer Immunology Research
Cited by 91

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Agonists of the TNF superfamily of receptors hold promise as novel therapy for cancer. Recent data on agonistic antimurine TNF receptors (TNFR) such as CD40 suggest that the specific engagement of Fc receptor (FcR) is required for optimal antitumor effects, prompting calls to engineer antihuman CD40 and other TNFR monoclonal antibodies (mAb) accordingly. CP-870,893 is a fully human anti-CD40 mAb, selected in part because it is an immunoglobulin G2 (IgG2), which is presumed to have poor reactivity with FcR; however, CP-870,893 has been evaluated in multiple clinical trials with beneficial activity in patients with melanoma, pancreatic, and other cancers. Here, we confirmed that the activity of antimurine CD40 mAb was dependent on FcγRIIB engagement, was decreased significantly in FcγRIIB−/− mice, and upon Fc-crosslinking antimouse CD40 mAb enhanced the activation of antigen-presenting cells. In contrast, the CP-870,893-mediated activation of human B cells was not enhanced with anti-IgG crosslinking nor abrogated when used as an F(ab)′2 reagent. Crosslinking of CP-870,893 using the CD32-expressing K562 cells yielded an Fc-dependent modest increase in the expression of some activation markers relative to that of the soluble CP-870,893 mAb. Classic Fc-dependent functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-mediated cytotoxicity (CMC) were minimal for CP-870,893 as compared with the IgG1 anti-CD20 mAb rituximab, which mediated both ADCC and CMC in parallel assays. Antimouse CD40 mAb competed for the CD40 ligand binding site, but CP-870,893 did not. Thus, Fc crosslinking is not an essential requirement for agonistic antihuman CD40 mAbs, in which potency is more dependent on the CD40 epitope recognized and the strength of the signal achieved. Cancer Immunol Res; 2(1); 19–26. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-13-0152

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 91

Metadata

Authors
Richman, L. P., & Vonderheide, R. H.
Venue
Cancer Immunology Research
Published
2014-01-01
Volume
2
Issue
1
Pages
19-26
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2169772944
Cited by
91
References
4
FWCI
4.99
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer. https://app.cochat.ai/papers/10.1158/2326-6066.cir-13-0152
The paper
Richman, L. P., & Vonderheide, R. H. (2014). Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-13-0152

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.